Skip to: Content
Skip to: Site Navigation
Skip to: Search
SUNDAY, NOVEMBER 22, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Novartis AG

Novartis AG stories: 4 news summaries

 Novartis Acquires Plavix Rival 

Novartis acquires worldwide rights from a San Francisco biopharmaceutical firm

Feb 12, 09 8:22 AM CST
(Newser) - Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion... More »

MORE ABOUT:
pharmaceutical companies • Eli Lilly • Lipitor • prasugrel • Plavix • Bristol Myers Squibb • Novartis AG • Portola Pharmaceuticals • elinogrel

Bone Drug Reduces Breast Cancer Relapse

Women on Zometa had 35% less chance of having tumor again

May 31, 08 7:21 PM CDT
(Newser) - A drug designed to protect cancer patients' bones also renders breast cancer relapses less likely, a new study says. Funded in part by the drug's maker, Novartis, researchers found that even two injections of Zometa a year cut tumor recurrence by 35% in more than 1,800 pre-menopausal women. More »

MORE ABOUT:
breast cancer • bone cancer • off label drug use • osteoporosis • Novartis AG • scientific study • Zometa

Drug Therapy Cuts Risk
of Breast Cancer Relapse

Aromatase inhibitors work after tamoxifen regimen ends

Mar 11, 08 7:16 AM CDT
(Newser) - New research shows that women can cut the risk of breast cancer recurring years later by taking certain drugs, the Washington Post reports. Studies show that the drugs, known as aromatase inhibitors, sharply reduced the risk of cancer's return after women had finished their regimen of the widely used tamoxifen.... More »

MORE ABOUT:
cancer • breast cancer • drugs • estrogen • cancer research • Novartis AG • Femara • tamoxifen • Aromasin • Dana-Farber Cancer Institute

Beefed-Up R&D Slows Drug Approval

Just 19 new meds cleared FDA in 2007

Jan 8, 08 5:45 PM CST
(Newser) - The FDA approved only 19 new drugs in 2007, the lowest total in 24 years. Bloomberg takes a look at the reasons. Some drug companies accuse the FDA of setting the bar higher for drug approvals, a charge the agency denies. Many, however, say the issue lies with big pharma... More »

MORE ABOUT:
FDA • drug safety • GlaxoSmithKline • Viviant • Tykerb • Novartis AG • Tasigna

4 Stories


from our news partners